Last reviewed · How we verify

NCT00001397

Evaluation, Treatment, and Training for Patients With Blood Disorders

Completed Last updated 8 October 2020
What this trial tests

trial in Hematologic Diseases in 1,452 participants. Completed in 5 October 2020.

Timeline
8 November 1993
Primary endpoint
5 October 2020
5 October 2020

Quick facts

Lead sponsorNational Heart, Lung, and Blood Institute (NHLBI)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,452
Start date8 November 1993
Primary completion5 October 2020
Estimated completion5 October 2020
Sites1 location across United States

Conditions studied

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 2 to 110, any sex, with Hematologic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) or not being screened for participation in a study. The purpose of this study is to allow investigation into the blood disorders of patients in order to teach, learn, and gather more information about diseases of the blood. In addition, this study allows researchers the opportunity to evaluate patients referred to the Hematology Branch of the NHLBI with rare or undiagnosed diseases of the blood. This may be potentially beneficial to the patient and at the same time contribute to the development of new research ideas.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells.
    Zhao X, Zhao X, Gao S, Wu Z, et al · · 2017 · cited 52× · PMID 29030335 · DOI 10.1182/blood-2017-08-803353
  2. Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes.
    Giudice V, Wu Z, Kajigaya S, Fernandez Ibanez MDP, et al · · 2019 · cited 37× · PMID 29958797 · DOI 10.1016/j.cyto.2018.06.025
  3. Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow.
    Wu Z, Gao S, Zhao X, Chen J, et al · · 2019 · cited 30× · PMID 30545929 · DOI 10.3324/haematol.2018.208926
  4. Interleukin-18 plays a dispensable role in murine and likely also human bone marrow failure.
    Wu Z, Giudice V, Chen J, Sun W, et al · · 2019 · cited 10× · PMID 30316805 · DOI 10.1016/j.exphem.2018.10.003
  5. Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.
    Popescu B, Sheela S, Thompson J, Grasmeder S, et al · · 2020 · cited 6× · PMID 32190831 · DOI 10.2991/chi.d.191128.001
  6. High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndrome-implication for the utility of serial biomarker monitoring.
    Nunes AT, Jain P, Kleiner DE, Shah NN, et al · · 2017 · PMID 28287645 · DOI 10.1038/bmt.2017.38

Verify or expand the search:

Other recruiting trials for Hematologic Diseases

Currently open trials in the same condition.

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing